Lupus & antiphospholipid syndrome
KLRG1 is reduced on NK cells in systemic lupus erythematosus (SLE) patients, inversely correlates with disease activity and is modulated by hydroxychloroquine in vitro
Authors' conclusion
With this study we revealed a reduced expression and an impaired function of KLRG1 on NK cells in SLE patients.
Study context
- Population
- SLE patients and healthy controls; Peripheral blood mononuclear cells (PBMCs) characterised by immunofluorescence and flow cytometry
- Participants
- 18 vs 12
- Comparison
- SLE patients vs healthy controls
- SLEn = 18
- Healthy controls (HC)n = 12reference
- Outcome
- KLRG1 expression on NK and T cells in SLE patients vs HC
Methodological detailsin vitro hydroxychloroquine (HCQ) treatment, flow cytometry
- In vitro HCQ treatment
- Flow cytometry
Main finding
As reported in the abstract
KLRG1 expression on immune cells
- KLRG1 expression significantly reduced on the analysed immune cell populations in SLE patients vs HC, especially on total NK cells
- KLRG1 expression on total NK cells inversely correlated with the SLEDAI-2K
- Direct association between KLRG1 expression on NK cells and patients' treatment with HCQ
- In vitro HCQ treatment increased KLRG1 expression on NK cells
- In HC, KLRG1+ NK cells showed reduced degranulation and IFNγ production; in SLE patients, inhibition only for IFNγ production
Original publication
KLRG1 is reduced on NK cells in SLE patients, inversely correlates with disease activity and is modulated by hydroxychloroquine in vitro. Lupus. Published 6 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →